Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 26, 2026 08:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Grand Cayman, May 26, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...
May 26, 2026 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
May 26, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...
May 26, 2026 08:00 ET | Source: Artios Pharma

Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer

Artios announces first patient dosed in randomized Phase 2 POLKA study evaluating DNA Polθ inhibitor ART6043 in gBRCA-mutated HER2-negative breast cancer.
May 22, 2026 09:42 ET | Source: 24/7 Market News

This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners

Biotechs continue attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy pla
May 22, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth
May 22, 2026 03:45 ET | Source: Boehringer Ingelheim Limited

China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis

Not intended for UK and US media Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in treatment-naïve patients1Expedited...
May 22, 2026 03:30 ET | Source: STORM Therapeutics

STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026

STORM Therapeutics announces that a subset analysis of sarcoma patients enrolled in the Phase 1 dose escalation study of STC-15 will be presented at ASCO.
May 21, 2026 17:05 ET | Source: Eikon Therapeutics, Inc.

Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology

The six accepted presentations highlight clinical progress across Eikon’s pipeline.
May 21, 2026 17:00 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026

Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2...